Resectable Head and Neck Squamous Cell Carcinoma Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Resectable Head and Neck Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2Phase 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting
Phase 1

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Locally Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell Carcinoma+3 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT04754321
Recruiting
Phase 1

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Resectable Head and Neck Squamous Cell CarcinomaHuman Papillomavirus-Negative Neck Squamous Cell CarcinomaResectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma+1 more
Mayo Clinic24 enrolled1 locationNCT06997094
Recruiting
Phase 2

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

Advanced Head and Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaStage II Head and Neck Cutaneous Squamous Cell Carcinoma+2 more
University of Michigan Rogel Cancer Center28 enrolled1 locationNCT07094685
Recruiting
Phase 2

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck CancerHead and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma+2 more
Dana-Farber Cancer Institute28 enrolled2 locationsNCT05726370